CTC Alternative Strategies’s Bristol-Myers Squibb BMY Stock Holding History

CTC Alternative Strategies’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,700	Closed	-$264K	–	97
2025 Q2	$264K	Sell	5,700 -4,500	-44%	-$221K	0.23%	118
2025 Q1	$622K	Buy	+10,200	New	+$595K	0.76%	31
2024 Q3	–	Sell	-10,034	Closed	-$417K	–	77
2024 Q2	$417K	Buy	+10,034	New	+$449K	0.18%	133
2013 Q3	–	Sell	-16,500	Closed	-$737K	–	106
2013 Q2	$737K	Buy	+16,500	New	+$716K	0.2%	37

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CTC Alternative Strategies's BMY Position: Q3 2025 in Review

CTC Alternative Strategies sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 5,700 shares — an estimated $264K sold.

CTC Alternative Strategies first reported a position in BMY in Q2 2013 and held it in 4 quarters. The position peaked at $737K in Q2 2013. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

CTC Alternative Strategies reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
CTC Alternative Strategies sold 5,700 Bristol-Myers Squibb shares in Q3 2025, an estimated $264K.
CTC Alternative Strategies first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 4 quarters.
CTC Alternative Strategies's Bristol-Myers Squibb position peaked at $737K in Q2 2013.
2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on CTC Alternative Strategies's 13F filing for Q3 2025, filed 15 Dec 2025.